Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VI9P
|
|||
| Former ID |
DIB000213
|
|||
| Drug Name |
OPN-305
|
|||
| Synonyms |
OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1] | |
| Company |
Opsona therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01794663) Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function. U.S. National Institutes of Health. | |||
| REF 2 | Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.